Trial Profile

Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMF 001 (Primary) ; MIS 416 (Primary)
Indications Prostate cancer; Urogenital cancer
Focus Adverse reactions; First in man

Most Recent Events

05 Jun 2018 Results (n=26) assessing safety, tolerabilty and immune response ( UMIN000008007 and UMIN000005246) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
14 Mar 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com